LYRA
Lyra Therapeutics Inc
NASDAQ · Pharmaceuticals
$1.82
+0.05 (+2.82%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 655.7K | 681.7K | 558.5K |
| Net Income | 178.6K | 169.3K | 107.5K |
| EPS | — | — | — |
| Profit Margin | 27.2% | 24.8% | 19.3% |
| Rev Growth | +5.2% | +3.7% | -9.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 993.7K | 1.04M | 1.08M |
| Total Equity | 1.67M | 1.55M | 1.59M |
| D/E Ratio | 0.60 | 0.67 | 0.68 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 306.3K | 337.6K | 271.6K |
| Free Cash Flow | 107.5K | 110.0K | 71.2K |